Fangda represented Shanghai Brattea Medical Technology Co., Ltd. (“Brattea”) in its series D investment. The transaction was closed in March 2024. Fangda team on this deal was led by partner Luo Ke, and the team members included Elaine Li and Joshua Tsui. Fangda assisted in the drafting and negotiation of transaction documents and the closing process. Brattea mainly engages in the R&D of medical devices in relation to nerve radiofrequency ablation, including Renal denervation (RDN) for hypertension.
Fangda assists Brattea in completing its high-value series-D financing
2024 / 04 / 24
READ MORE
2026 / 08 / 04
Fangda Advises CITIC Capital on HK$600 Million Victoria Harbour Nexus Innovation LPF, the First Fund Established under Hong Kong ITVF Enhanced Scheme
2026 / 07 / 31
Fangda Advises Keboda on its Public Offering of Convertible Corporate Bonds
2026 / 07 / 09
Fangda Assists Biren Technology on its HKD7 Billion H-share Placement
2026 / 07 / 07
“The first physical AI stock” — Fangda Advises Momenta on its successful Hong Kong listing
2026 / 07 / 06
Fangda Advised BlueFive and Primavera Capital on Equity Investment in Kling AI
